REVELATION BIOSCIENCES INC
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
REVB$3.94-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Operations
| Year EndedDecember 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| Research and development | $3,548,996 | $4,145,902 |
| General and administrative | 4,426,113 | 4,510,762 |
| Total operating expenses | 7,975,109 | 8,656,664 |
| Loss from operations | (7,975,109) | (8,656,664) |
| Other (expense) income: | ||
| Change in fair value of warrant liability | 81,441 | 8,328,937 |
| Other (expense) income, net | (7,144,868) | 207,473 |
| Total other (expense) income, net | (7,063,427) | 8,536,410 |
| Net loss | $(15,038,536) | $(120,254) |
| Net loss per share, basic and diluted | $(87.68) | $(8.44) |
| Weighted-average shares used to compute net loss per share, basic and diluted | 171,510 | 14,246 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.